Active Pharmaceutical Ingredient Market

Global Market Study on Active Pharmaceutical Ingredients: Pharmaceutical Companies to Lead Market Growth

Active Pharmaceutical Ingredients Market Segmented By Small Molecules, Non-Controlled Substances, HPAPI, Peptides and Oligonucleotides, Carbohydrate Drugs, Steroidal Drugs API Type

  • May-2021
  • PMRREP11260
  • 250 Pages
  • Healthcare
  • PPT, PDF, WORD, EXCEL

Table of Content

1. Executive Summary

    1.1. Global Market Outlook

    1.2. Demand Side Trends

    1.3. Supply Side Trends

    1.4. Analysis and Recommendations

2. Market Overview

    2.1. Market Coverage / Taxonomy

    2.2. Market Definition / Scope / Limitations

3. Key Market Trends

    3.1. Key Trends Impacting the Market

    3.2. Product Innovation / Development Trends

4. Key Success Factors

    4.1. Product Adoption / Usage Analysis

    4.2. Regulatory Scenario

5. Market Background

    5.1. Macro-Economic Factors

        5.1.1. Global GDP Growth Outlook

        5.1.2. Healthcare Expenditure by Country

        5.1.3. Regional Healthcare Market Outlook

    5.2. Forecast Factors - Relevance & Impact

        5.2.1. New Product Launches 

        5.2.2. Production Capacity 

        5.2.3. Demand for Therapeutic Medicines

        5.2.4. Prevalence of Chronic Diseases

        5.2.5. R & D Expenditure

        5.2.6. Annual Growth Rate of Key Companies

    5.3. Value Chain

    5.4. Market Dynamics

        5.4.1. Drivers

        5.4.2. Restraints

        5.4.3. Opportunity Analysis

6. COVID19 Crisis Analysis

    6.1. Current COVID19 Perspective and Probable Future Impact

    6.2. Current GDP Projection and Probable Impact

    6.3. Current Economic Projection as compared to 2008 Economic analysis

    6.4. COVID19 and Impact Analysis

            6.4.1.1. Revenue By API Type

            6.4.1.2. Revenue By End User

            6.4.1.3. Revenue By Country

    6.5. 2021 Market Scenario

    6.6. Recovery Scenario – Short term, Midterm and Long Term Impact

7. Global Active Pharmaceutical Ingredient Market Demand (in Value or Size in US$ Mn) Analysis 2016-2020 and Forecast, 2021-2031

    7.1. Historical Market Value (US$ Mn) Analysis, 2016-2020

    7.2. Current and Future Market Value (US$ Mn) Projections, 2021-2031

        7.2.1. Y-o-Y Growth Trend Analysis

        7.2.2. Absolute $ Opportunity Analysis

8. Global Active Pharmaceutical Ingredient Market Analysis 2016-2020 and Forecast 2021-2031, by API Type 

    8.1. Introduction / Key Findings

    8.2. Historical Market Size (US$ Mn) Analysis By API Type, 2016 - 2020

    8.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By API Type, 2021 - 2031

        8.3.1. Small Molecules

            8.3.1.1. Controlled Substances

                8.3.1.1.1. Natural Opioids

                8.3.1.1.2. Semi-synthetic/Synthetic Opioids

            8.3.1.2. Non-Controlled Substances

                8.3.1.2.1. NSAIDs

                8.3.1.2.2. Anti-infective

                8.3.1.2.3. Antimicrobial

                8.3.1.2.4. Oral anti-diabetics

                8.3.1.2.5. Anti-hypertensive

                8.3.1.2.6. Others

            8.3.1.3. HPAPI

        8.3.2. Peptides & Oligonucleotides

        8.3.3. Carbohydrate Drugs

        8.3.4. Steroidal Drugs

    8.4. Market Attractiveness Analysis By API Type 

9. Global Active Pharmaceutical Ingredient Market Analysis 2016-2020 and Forecast 2021-2031, by End User

    9.1. Introduction / Key Findings

    9.2. Historical Market Size (US$ Mn) Analysis By End User, 2016 - 2020

    9.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By End User, 2021 - 2031

        9.3.1. Pharmaceutical Companies

        9.3.2. Biopharmaceutical Companies

        9.3.3. Contract Manufacturing Organizations (CMOs)

        9.3.4. Contract Development & Manufacturing Organization (CDMO)

    9.4. Market Attractiveness Analysis By End User

10. Global Active Pharmaceutical Ingredient Market Analysis 2016-2020 and Forecast 2021-2031, by Region

    10.1. Introduction

    10.2. Historical Market Size (US$ Mn) Analysis By Region, 2016 - 2020

    10.3. Current Market Size (US$ Mn) Analysis and Forecast By Region, 2021- 2031

        10.3.1. North America

        10.3.2. Latin America

        10.3.3. Europe

        10.3.4. South Asia

        10.3.5. East Asia

        10.3.6. Oceania

        10.3.7. Middle East and Africa

    10.4. Market Attractiveness Analysis By Region

11. North America Active Pharmaceutical Ingredient Market Analysis 2016-2020 and Forecast 2021-2031

    11.1. Introduction

    11.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2016 - 2020

    11.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2021 - 2031

        11.3.1. By Country

            11.3.1.1. U.S.

            11.3.1.2. Canada

        11.3.2. By API Type

        11.3.3. By End User

    11.4. Market Attractiveness Analysis

    11.5. Drivers and Restraints - Impact Analysis

12. Latin America Active Pharmaceutical Ingredient Market Analysis 2016-2020 and Forecast 2021-2031

    12.1. Introduction

    12.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2016 - 2020

    12.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2021 - 2031

        12.3.1. By Country

            12.3.1.1. Brazil

            12.3.1.2. Mexico

            12.3.1.3. Rest of Latin America

        12.3.2. By API Type

        12.3.3. By End User

    12.4. Market Attractiveness Analysis

    12.5. Drivers and Restraints - Impact Analysis

13. Europe Active Pharmaceutical Ingredient Market Analysis 2016-2020 and Forecast 2021-2031

    13.1. Introduction

    13.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2016 - 2020

    13.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2021 - 2031

        13.3.1. By Country

            13.3.1.1. Germany

            13.3.1.2. Italy

            13.3.1.3. France

            13.3.1.4. U.K.

            13.3.1.5. Spain

            13.3.1.6. BENELUX

            13.3.1.7. Russia

            13.3.1.8. Rest of Europe

        13.3.2. By API Type

        13.3.3. By End User

    13.4. Market Attractiveness Analysis

    13.5. Drivers and Restraints - Impact Analysis

14. South Asia Active Pharmaceutical Ingredient Market Analysis 2016-2020 and Forecast 2021-2031

    14.1. Introduction

    14.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2016 - 2020

    14.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2021 - 2031

        14.3.1. By Country

            14.3.1.1. India

            14.3.1.2. Thailand

            14.3.1.3. Indonesia

            14.3.1.4. Malaysia

            14.3.1.5. Rest of South Asia

        14.3.2. By API Type

        14.3.3. By End User

    14.4. Market Attractiveness Analysis

    14.5. Drivers and Restraints - Impact Analysis

15. East Asia Active Pharmaceutical Ingredient Market Analysis 2016-2020 and Forecast 2021-2031

    15.1. Introduction

    15.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2016 - 2020

    15.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2021 - 2031

        15.3.1. By Country

            15.3.1.1. China

            15.3.1.2. Japan

            15.3.1.3. South Korea

        15.3.2. By API Type

        15.3.3. By End User

    15.4. Market Attractiveness Analysis

    15.5. Drivers and Restraints - Impact Analysis

16. Oceania Active Pharmaceutical Ingredient Market Analysis 2016-2020 and Forecast 2021-2031

    16.1. Introduction

    16.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2016 - 2020

    16.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2021 - 2031

        16.3.1. By Country

            16.3.1.1. Australia

            16.3.1.2. New Zealand

        16.3.2. By API Type

        16.3.3. By End User

    16.4. Market Attractiveness Analysis

    16.5. Drivers and Restraints - Impact Analysis

17. Middle East and Africa Active Pharmaceutical Ingredient Market Analysis 2016-2020 and Forecast 2021-2031

    17.1. Introduction

    17.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2016 - 2020

    17.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2021 - 2031

        17.3.1. By Country

            17.3.1.1. GCC Countries

            17.3.1.2. Turkey

            17.3.1.3. Northern Africa

            17.3.1.4. South Africa

            17.3.1.5. Rest of Middle East and Africa

        17.3.2. By API Type

        17.3.3. By End User

    17.4. Market Attractiveness Analysis

    17.5. Drivers and Restraints - Impact Analysis

18. Key and Emerging Countries Active Pharmaceutical Ingredient Market Analysis 2016-2020  and Forecast 2021-2031 

    18.1. Introduction

        18.1.1. Market Value Proportion Analysis, By Key Countries

        18.1.2. Global Vs. Country Growth Comparison

    18.2. U.S. Active Pharmaceutical Ingredient Market Analysis

        18.2.1. By API Type

        18.2.2. By End User

    18.3. Canada Active Pharmaceutical Ingredient Market Analysis

        18.3.1. By API Type

        18.3.2. By End User

    18.4. Mexico Active Pharmaceutical Ingredient Market Analysis

        18.4.1. By API Type

        18.4.2. By End User

    18.5. Brazil Active Pharmaceutical Ingredient Market Analysis

        18.5.1. By API Type

        18.5.2. By End User

    18.6. U.K. Active Pharmaceutical Ingredient Market Analysis

        18.6.1. By API Type

        18.6.2. By End User

    18.7. Germany Active Pharmaceutical Ingredient Market Analysis

        18.7.1. By API Type

        18.7.2. By End User

    18.8. France Active Pharmaceutical Ingredient Market Analysis

        18.8.1. By API Type

        18.8.2. By End User

    18.9. Italy Active Pharmaceutical Ingredient Market Analysis

        18.9.1. By API Type

        18.9.2. By End User

    18.10. Spain Active Pharmaceutical Ingredient Market Analysis

        18.10.1. By API Type

        18.10.2. By End User

    18.11. Russia Active Pharmaceutical Ingredient Market Analysis

        18.11.1. By API Type

        18.11.2. By End User

    18.12. China Active Pharmaceutical Ingredient Market Analysis

        18.12.1. By API Type

        18.12.2. By End User

    18.13. Japan Active Pharmaceutical Ingredient Market Analysis

        18.13.1. By API Type

        18.13.2. By End User

    18.14. South Korea Active Pharmaceutical Ingredient Market Analysis

        18.14.1. By API Type

        18.14.2. By End User

    18.15. India Active Pharmaceutical Ingredient Market Analysis

        18.15.1. By API Type

        18.15.2. By End User

    18.16. Thailand Active Pharmaceutical Ingredient Market Analysis

        18.16.1. By API Type

        18.16.2. By End User

    18.17. Indonesia Active Pharmaceutical Ingredient Market Analysis

        18.17.1. By API Type

        18.17.2. By End User 

    18.18. Malaysia Active Pharmaceutical Ingredient Market Analysis

        18.18.1. By Product

        18.18.2. By End User 

    18.19. Australia Active Pharmaceutical Ingredient Market Analysis

        18.19.1. By API Type

        18.19.2. By End User

    18.20. New Zealand Active Pharmaceutical Ingredient Market Analysis

        18.20.1. By API Type

        18.20.2. By End User

    18.21. GCC Countries Active Pharmaceutical Ingredient Market Analysis

        18.21.1. By API Type

        18.21.2. By End User

    18.22. Turkey Active Pharmaceutical Ingredient Market Analysis

        18.22.1. By API Type

        18.22.2. By End User

    18.23. South Africa Active Pharmaceutical Ingredient Market Analysis

        18.23.1. By API Type

        18.23.2. By End User

19. Competition Analysis

    19.1. Competition Dashboard

    19.2. Company Deep Dive 

        19.2.1. Pfizer Inc.

            19.2.1.1. Overview

            19.2.1.2. Product Portfolio

            19.2.1.3. Sales Footprint

            19.2.1.4. Strategy Overview

                19.2.1.4.1. Marketing Strategy

                19.2.1.4.2. Product Strategy

                19.2.1.4.3. Channel Strategy

        19.2.2. Boehringer Ingelheim International GmbH

            19.2.2.1. Overview

            19.2.2.2. Product Portfolio

            19.2.2.3. Sales Footprint

            19.2.2.4. Strategy Overview

                19.2.2.4.1. Marketing Strategy

                19.2.2.4.2. Product Strategy

                19.2.2.4.3. Channel Strategy

        19.2.3. Bristol-Myers Squibb Company

            19.2.3.1. Overview

            19.2.3.2. Product Portfolio

            19.2.3.3. Sales Footprint

            19.2.3.4. Strategy Overview

                19.2.3.4.1. Marketing Strategy

                19.2.3.4.2. Product Strategy

                19.2.3.4.3. Channel Strategy

        19.2.4. Cipla Inc.

            19.2.4.1. Overview

            19.2.4.2. Product Portfolio

            19.2.4.3. Sales Footprint

            19.2.4.4. Strategy Overview

                19.2.4.4.1. Marketing Strategy

                19.2.4.4.2. Product Strategy

                19.2.4.4.3. Channel Strategy

        19.2.5. Eli Lilly and Company

            19.2.5.1. Overview

            19.2.5.2. Product Portfolio

            19.2.5.3. Sales Footprint

            19.2.5.4. Strategy Overview

                19.2.5.4.1. Marketing Strategy

                19.2.5.4.2. Product Strategy

                19.2.5.4.3. Channel Strategy

        19.2.6. F. Hoffmann-La Roche Ltd

            19.2.6.1. Overview

            19.2.6.2. Product Portfolio

            19.2.6.3. Sales Footprint

            19.2.6.4. Strategy Overview

                19.2.6.4.1. Marketing Strategy

                19.2.6.4.2. Product Strategy

                19.2.6.4.3. Channel Strategy

        19.2.7. GlaxoSmithKline plc

            19.2.7.1. Overview

            19.2.7.2. Product Portfolio

            19.2.7.3. Sales Footprint

            19.2.7.4. Strategy Overview

                19.2.7.4.1. Marketing Strategy

                19.2.7.4.2. Product Strategy

                19.2.7.4.3. Channel Strategy

        19.2.8. Hepalink Group

            19.2.8.1. Overview

            19.2.8.2. Product Portfolio

            19.2.8.3. Sales Footprint

            19.2.8.4. Strategy Overview

                19.2.8.4.1. Marketing Strategy

                19.2.8.4.2. Product Strategy

                19.2.8.4.3. Channel Strategy

        19.2.9. Lonza

            19.2.9.1. Overview

            19.2.9.2. Product Portfolio

            19.2.9.3. Sales Footprint

            19.2.9.4. Strategy Overview

                19.2.9.4.1. Marketing Strategy

                19.2.9.4.2. Product Strategy

                19.2.9.4.3. Channel Strategy

        19.2.10. Merck & Co. Inc.

            19.2.10.1. Overview

            19.2.10.2. Product Portfolio

            19.2.10.3. Sales Footprint

            19.2.10.4. Strategy Overview

                19.2.10.4.1. Marketing Strategy

                19.2.10.4.2. Product Strategy

                19.2.10.4.3. Channel Strategy

        19.2.11. Sandoz International GmbH

            19.2.11.1. Overview

            19.2.11.2. Product Portfolio

            19.2.11.3. Sales Footprint

            19.2.11.4. Strategy Overview

                19.2.11.4.1. Marketing Strategy

                19.2.11.4.2. Product Strategy

                19.2.11.4.3. Channel Strategy

        19.2.12. Aurobindo Pharma Limited

            19.2.12.1. Overview

            19.2.12.2. Product Portfolio

            19.2.12.3. Sales Footprint

            19.2.12.4. Strategy Overview

                19.2.12.4.1. Marketing Strategy

                19.2.12.4.2. Product Strategy

                19.2.12.4.3. Channel Strategy

        19.2.13. Fresenius Kabi LLC

            19.2.13.1. Overview

            19.2.13.2. Product Portfolio

            19.2.13.3. Sales Footprint

            19.2.13.4. Strategy Overview

                19.2.13.4.1. Marketing Strategy

                19.2.13.4.2. Product Strategy

                19.2.13.4.3. Channel Strategy

20. Assumptions and Acronyms Used

21. Research Methodology

Find Out More about the Report Coverage

List of Tables

Table 01: Global Active Pharmaceutical Ingredient Market Value (US$ Bn) Analysis 2016–2020 and Forecast 2021–2031, by End User

Table 02: Global Active Pharmaceutical Ingredient Market Value (US$ Bn) Analysis 2016–2020 and Forecast 2021–2031, by Country

Table 03: North America Active Pharmaceutical Ingredient Market Value (US$ Bn) Analysis 2016-2020 and Forecast 2021-2031, by Country

Table 04: North America Active Pharmaceutical Ingredient Market Value (US$ Bn) Analysis 2016–2020 and Forecast 2021–2031, by End User

Table 05: Latin America Active Pharmaceutical Ingredient Market Value (US$ Bn) Analysis 2016-2020 and Forecast 2021-2031, by Country

Table 06: Latin America Active Pharmaceutical Ingredient Market Value (US$ Bn) Analysis 2016–2020 and Forecast 2021–2031, by End User

Table 07: Europe Active Pharmaceutical Ingredient Market Value (US$ Bn) Analysis 2016-2020 and Forecast 2021-2031, by Country

Table 08: Europe Active Pharmaceutical Ingredient Market Value (US$ Bn) Analysis 2016–2020 and Forecast 2021–2031, by End User

Table 09: South Asia Active Pharmaceutical Ingredient Market Value (US$ Bn) Analysis 2016-2020 and Forecast 2021-2031, by Country

Table 10: South Asia Active Pharmaceutical Ingredient Market Value (US$ Bn) Analysis 2016–2020 and Forecast 2021–2031, by End User

Table 11: East Asia Active Pharmaceutical Ingredient Market Value (US$ Bn) Analysis 2016-2020 and Forecast 2021-2031, by Country

Table 12: East Asia Active Pharmaceutical Ingredient Market Value (US$ Bn) Analysis 2016–2020 and Forecast 2021–2031, by End User

Table 13: Oceania Active Pharmaceutical Ingredient Market Value (US$ Bn) Analysis 2016-2020 and Forecast 2021-2031, by Country

Table 14: Oceania Active Pharmaceutical Ingredient Market Value (US$ Bn) Analysis 2016–2020 and Forecast 2021–2031, by End User

Table 15: MEA Active Pharmaceutical Ingredient Market Value (US$ Bn) Analysis 2016-2020 and Forecast 2021-2031, by Country

Table 16: MEA Active Pharmaceutical Ingredient Market Value (US$ Bn) Analysis 2016–2020 and Forecast 2021–2031, by End User

Table 17: Global Active Pharmaceutical Ingredient Market Value (US$ Bn) Analysis 2016–2020 and Forecast 2021–2031, by API Type

Table 18: Global Active Pharmaceutical Ingredient Market Value (US$ Bn) Analysis 2016–2020 and Forecast 2021–2031, by API Type

Table 19: North America Active Pharmaceutical Ingredient Market Value (US$ Bn) Analysis 2016–2020 and Forecast 2021–2031, by API Type

Table 20: North America Active Pharmaceutical Ingredient Market Value (US$ Bn) Analysis 2016–2020 and Forecast 2021–2031, by API Type

Table 21: Latin America Active Pharmaceutical Ingredient Market Value (US$ Bn) Analysis 2016–2020 and Forecast 2021–2031, by API Type

Table 22: Latin America Active Pharmaceutical Ingredient Market Value (US$ Bn) Analysis 2016–2020 and Forecast 2021–2031, by API Type

Table 23: Europe Active Pharmaceutical Ingredient Market Value (US$ Bn) Analysis 2016–2020 and Forecast 2021–2031, by API Type

Table 24: Europe Active Pharmaceutical Ingredient Market Value (US$ Bn) Analysis 2016–2020 and Forecast 2021–2031, by API Type

Table 25: South Asia Active Pharmaceutical Ingredient Market Value (US$ Bn) Analysis 2016–2020 and Forecast 2021–2031, by API Type

Table 26: South Asia Active Pharmaceutical Ingredient Market Value (US$ Bn) Analysis 2016–2020 and Forecast 2021–2031, by API Type

Table 27: East Asia Active Pharmaceutical Ingredient Market Value (US$ Bn) Analysis 2016–2020 and Forecast 2021–2031, by API Type

Table 28: East Asia Active Pharmaceutical Ingredient Market Value (US$ Bn) Analysis 2016–2020 and Forecast 2021–2031, by API Type

Table 29: Oceania Active Pharmaceutical Ingredient Market Value (US$ Bn) Analysis 2016–2020 and Forecast 2021–2031, by API Type

Table 30: Oceania Active Pharmaceutical Ingredient Market Value (US$ Bn) Analysis 2016–2020 and Forecast 2021–2031, by API Type

Table 31: MEA Active Pharmaceutical Ingredient Market Value (US$ Bn) Analysis 2016–2020 and Forecast 2021–2031, by API Type

Table 32: MEA Active Pharmaceutical Ingredient Market Value (US$ Bn) Analysis 2016–2020 and Forecast 2021–2031, by API Type

Explore Persistence Market Research’s expertise in promulgation of the business !

List of Chart

Figure 01:Global Active Pharmaceutical Ingredient Market Value (US$ Bn) by API Type, 2021 & 2031

Figure 02: Global Active Pharmaceutical Ingredient Market Value Analysis (US$ Bn), 2016-2020

Figure 03: Global Active Pharmaceutical Ingredient Market Value Forecast (US$ Bn), 2021-2031

Figure 04: Global Active Pharmaceutical Ingredient Market Absolute $ Opportunity, 2021–2031

Figure 05: Global Active Pharmaceutical Ingredient Market Share Analysis (%) by API Type, 2021 & 2031

Figure 06: Global Active Pharmaceutical Ingredient Market Y-o-Y Growth (%) by, 2020–2031

Figure 07: Global Active Pharmaceutical Ingredient Market Attractiveness Analysis by API Type, 2021–2031

Figure 08: Global Active Pharmaceutical Ingredient Market Share Analysis (%) by End User, 2021 & 2031

Figure 09: Global Active Pharmaceutical Ingredient Market Y-o-Y Growth (%) by End User, 2020–2031

Figure 10: Global Active Pharmaceutical Ingredient Market Attractiveness Analysis by End User, 2021–2031

Figure 11: Global Active Pharmaceutical Ingredient Market Share Analysis (%) by Country, 2021 & 2031

Figure 12: Global Active Pharmaceutical Ingredient Market Y-o-Y Growth (%) by Country, 2021–2031

Figure 13: Global Active Pharmaceutical Ingredient Market Attractiveness Analysis by Country, 2021–2031

Figure 14: North America Active Pharmaceutical Ingredient Market Value Share, By API Type, 2021 (E)

Figure 15: North America Active Pharmaceutical Ingredient Market Value Share, By End User, 2021 (E)

Figure 16: North America Market Value Share, By Country, 2021 (E)

Figure 17: North America Active Pharmaceutical Ingredient Market Value (US$ Bn), 2016 – 2020

Figure 18: North America Active Pharmaceutical Ingredient Market Value (US$ Bn) Forecast, 2021–2031

Figure 19: North America Active Pharmaceutical Ingredient Market Attractiveness Analysis by API Type, 2021-2031

Figure 20: North America Active Pharmaceutical Ingredient Market Attractiveness Analysis by End User , 2021-2031

Figure 21: North America Active Pharmaceutical Ingredient Market Attractiveness Analysis by Country, 2021-2031

Figure 22: Latin America Active Pharmaceutical Ingredient Market Value Share, By API Type, 2021 (E)

Figure 23: Latin America Active Pharmaceutical Ingredient Market Value Share, By End User, 2021 (E)

Figure 24: Latin America Market Value Share, By Country, 2021 (E)

Figure 25: Latin America Active Pharmaceutical Ingredient Market Value (US$ Bn), 2016 – 2020

Figure 26: Latin America Active Pharmaceutical Ingredient Market Value (US$ Bn) Forecast, 2021–2031

Figure 27: Latin America Active Pharmaceutical Ingredient Market Attractiveness Analysis by API Type, 2021-2031

Figure 28: Latin America Active Pharmaceutical Ingredient Market Attractiveness Analysis by End User , 2021-203128

Figure 29: Latin America Active Pharmaceutical Ingredient Market Attractiveness Analysis by Country, 2021-2031

Figure 30: Europe Active Pharmaceutical Ingredient Market Value Share, By API Type, 2021 (E)

Figure 31: Europe Active Pharmaceutical Ingredient Market Value Share, By End User, 2021 (E)

Figure 32: Europe Market Value Share, By Country, 2021 (E)

Figure 33: Europe Active Pharmaceutical Ingredient Market Value (US$ Bn), 2016 – 2020

Figure 34: Europe Active Pharmaceutical Ingredient Market Value (US$ Bn) Forecast, 2021–2031

Figure 35: Europe Active Pharmaceutical Ingredient Market Attractiveness Analysis by API Type, 2021-2031

Figure 36: Europe Active Pharmaceutical Ingredient Market Attractiveness Analysis by End User , 2021-2031

Figure 37: Europe Active Pharmaceutical Ingredient Market Attractiveness Analysis by Country, 2021-2031

Figure 38: South Asia Active Pharmaceutical Ingredient Market Value Share, By API Type, 2021 (E)

Figure 39: South Asia Active Pharmaceutical Ingredient Market Value Share, By End User, 2021 (E)

Figure 40: South Asia Market Value Share, By Country, 2021 (E)

Figure 41: South Asia Active Pharmaceutical Ingredient Market Value (US$ Bn), 2016 – 2020

Figure 42: South Asia Active Pharmaceutical Ingredient Market Value (US$ Bn) Forecast, 2021–2031

Figure 43: South Asia Active Pharmaceutical Ingredient Market Attractiveness Analysis by API Type, 2021-2031

Figure 44: South Asia Active Pharmaceutical Ingredient Market Attractiveness Analysis by End User , 2021-2031

Figure 45: South Asia Active Pharmaceutical Ingredient Market Attractiveness Analysis by Country, 2021-2031

Figure 46: East Asia Active Pharmaceutical Ingredient Market Value Share, By API Type, 2021 (E)

Figure 47: East Asia Active Pharmaceutical Ingredient Market Value Share, By End User, 2021 (E)

Figure 48: East Asia Market Value Share, By Country, 2021 (E)

Figure 49: East Asia Active Pharmaceutical Ingredient Market Value (US$ Bn), 2016 – 2020

Figure 50: East Asia Active Pharmaceutical Ingredient Market Value (US$ Bn) Forecast, 2021–2031

Figure 51: East Asia Active Pharmaceutical Ingredient Market Attractiveness Analysis by API Type, 2021-2031

Figure 52: East Asia Active Pharmaceutical Ingredient Market Attractiveness Analysis by End User , 2021-2031

Figure 53: East Asia Active Pharmaceutical Ingredient Market Attractiveness Analysis by Country, 2021-2031

Figure 54: Oceania Active Pharmaceutical Ingredient Market Value Share, By API Type, 2021 (E)

Figure 55: Oceania Active Pharmaceutical Ingredient Market Value Share, By End User, 2021 (E)

Figure 56: Oceania Market Value Share, By Country, 2021 (E)

Figure 57: Oceania Active Pharmaceutical Ingredient Market Value (US$ Bn), 2016 – 2020

Figure 58: Oceania Active Pharmaceutical Ingredient Market Value (US$ Bn) Forecast, 2021–2031

Figure 59: Oceania Active Pharmaceutical Ingredient Market Attractiveness Analysis by API Type, 2021-2031

Figure 60: Oceania Active Pharmaceutical Ingredient Market Attractiveness Analysis by End User , 2021-2031

Figure 61: East  Asia Active Pharmaceutical Ingredient Market Attractiveness Analysis by Country, 2021-2031

Figure 62: MEA Active Pharmaceutical Ingredient Market Value Share, By API Type, 2021 (E)

Figure 63: MEA Active Pharmaceutical Ingredient Market Value Share, By End User, 2021 (E)

Figure 64: MEA Market Value Share, By Country, 2021 (E)

Figure 65: MEA Active Pharmaceutical Ingredient Market Value (US$ Bn), 2016 – 2020

Figure 66: MEA Active Pharmaceutical Ingredient Market Value (US$ Bn) Forecast, 2021–2031

Figure 67: MEA Active Pharmaceutical Ingredient Market Attractiveness Analysis by API Type, 2021-2031

Figure 68: MEA Active Pharmaceutical Ingredient Market Attractiveness Analysis by End User , 2021-2031

Figure 69: MEA Active Pharmaceutical Ingredient Market Attractiveness Analysis by Country, 2021-2031

Figure 70: U.S. Active Pharmaceutical Ingredient Market Share Analysis (%), By Product Type, 2020 &2031

Figure 71: U.S. Active Pharmaceutical Ingredient Market Share Analysis (%), By End User, 2020 &2031

Figure 72: Global Vs. U.S. Growth Comparison

Figure 73: Canada Active Pharmaceutical Ingredient Market Share Analysis (%), By Product Type, 2020 &2031

Figure 74: Canada Active Pharmaceutical Ingredient Market Share Analysis (%), By End User, 2020 &2031

Figure 75: Global Vs. Canada Growth Comparison

Figure 76: Mexico Active Pharmaceutical Ingredient Market Share Analysis (%), By Product Type, 2020 &2031

Figure 77: Mexico Active Pharmaceutical Ingredient Market Share Analysis (%), By End User, 2020 &2031

Figure 78: Global Vs. Mexico Growth Comparison

Figure 79: Brazil Active Pharmaceutical Ingredient Market Share Analysis (%), By Product Type, 2020 &2031

Figure 80: Brazil Active Pharmaceutical Ingredient Market Share Analysis (%), By End User, 2020 &2031

Figure 81: Global Vs. Brazil Growth Comparison

Figure 82: U.K. Active Pharmaceutical Ingredient Market Share Analysis (%), By Product Type, 2020 &2031

Figure 83: U.K. Active Pharmaceutical Ingredient Market Share Analysis (%), By End User, 2020 &2031

Figure 84: Global Vs. U.K. Growth Comparison

Figure 85: Germany Active Pharmaceutical Ingredient Market Share Analysis (%), By Product Type, 2020 &2031

Figure 86: Germany Active Pharmaceutical Ingredient Market Share Analysis (%), By End User, 2020 &2031

Figure 87: Global Vs. Germany Growth Comparison

Figure 88: France Active Pharmaceutical Ingredient Market Share Analysis (%), By Product Type, 2020 &2031

Figure 89: France Active Pharmaceutical Ingredient Market Share Analysis (%), By End User, 2020 &2031

Figure 90: Global Vs. France Growth Comparison

Figure 91: Italy Active Pharmaceutical Ingredient Market Share Analysis (%), By Product Type, 2020 &2031

Figure 92: Italy Active Pharmaceutical Ingredient Market Share Analysis (%), By End User, 2020 &2031

Figure 93: Global Vs. Italy Growth Comparison

Figure 94: Spain Active Pharmaceutical Ingredient Market Share Analysis (%), By Product Type, 2020 &2031

Figure 95: Spain Active Pharmaceutical Ingredient Market Share Analysis (%), By End User, 2020 &2031

Figure 96: Global Vs. Spain Growth Comparison

Figure 97: Russia Active Pharmaceutical Ingredient Market Share Analysis (%), By Product Type, 2020 &2031

Figure 99: Russia Active Pharmaceutical Ingredient Market Share Analysis (%), By End User, 2020 &2031

Figure 99: Global Vs. Russia Growth Comparison

Figure 100: China Active Pharmaceutical Ingredient Market Share Analysis (%), By Product Type, 2020 &2031

Figure 101: China Active Pharmaceutical Ingredient Market Share Analysis (%), By End User, 2020 &2031

Figure 102: Global Vs. China Growth Comparison

Figure 103: Japan Active Pharmaceutical Ingredient Market Share Analysis (%), By Product Type, 2020 &2031

Figure 104: Japan Active Pharmaceutical Ingredient Market Share Analysis (%), By End User, 2020 &2031

Figure 105: Global Vs. Japan Growth Comparison

Figure 106: South Korea Active Pharmaceutical Ingredient Market Share Analysis (%), By Product Type, 2020 &2031

Figure 107: South Korea Active Pharmaceutical Ingredient Market Share Analysis (%), By End User, 2020 &2031

Figure 108: Global Vs. South Korea Growth Comparison

Figure 109: India Active Pharmaceutical Ingredient Market Share Analysis (%), By Product Type, 2020 &2031

Figure 110: India Active Pharmaceutical Ingredient Market Share Analysis (%), By End User, 2020 &2031

Figure 111: Global Vs. India Growth Comparison

Figure 112: Thailand Active Pharmaceutical Ingredient Market Share Analysis (%), By Product Type, 2020 &2031

Figure 113: Thailand Active Pharmaceutical Ingredient Market Share Analysis (%), By End User, 2020 &2031

Figure 114: Global Vs. Thailand Growth Comparison

Figure 115: Indonesia Active Pharmaceutical Ingredient Market Share Analysis (%), By Product Type, 2020 &2031

Figure 116: Indonesia Active Pharmaceutical Ingredient Market Share Analysis (%), By End User, 2020 &2031

Figure 117: Global Vs. Indonesia Growth Comparison

Figure 118: Malaysia Active Pharmaceutical Ingredient Market Share Analysis (%), By Product Type, 2020 &2031

Figure 119: Malaysia Active Pharmaceutical Ingredient Market Share Analysis (%), By End User, 2020 &2031

Figure 120: Global Vs. Malaysia Growth Comparison

Figure 121: Australia Active Pharmaceutical Ingredient Market Share Analysis (%), By Product Type, 2020 &2031

Figure 122: Australia Active Pharmaceutical Ingredient Market Share Analysis (%), By End User, 2020 &2031

Figure 123: Global Vs. Australia Growth Comparison

Figure 124: New Zealand Active Pharmaceutical Ingredient Market Share Analysis (%), By Product Type, 2020 &2031

Figure 125: New Zealand Active Pharmaceutical Ingredient Market Share Analysis (%), By End User, 2020 &2031

Figure 126: Global Vs. New Zealand Growth Comparison

Figure 127: GCC Countries Active Pharmaceutical Ingredient Market Share Analysis (%), By Product Type, 2020 &2031

Figure 128: GCC Countries Active Pharmaceutical Ingredient Market Share Analysis (%), By End User, 2020 &2031

Figure 129: Global Vs. GCC Countries Growth Comparison

Figure 130: Turkey Active Pharmaceutical Ingredient Market Share Analysis (%), By Product Type, 2020 &2031

Figure 131: Turkey Active Pharmaceutical Ingredient Market Share Analysis (%), By End User, 2020 &2031

Figure 132: Global Vs. Turkey Growth Comparison

Figure 133: South Africa Active Pharmaceutical Ingredient Market Share Analysis (%), By Product Type, 2020 &2031

Figure 134: South Africa Active Pharmaceutical Ingredient Market Share Analysis (%), By End User, 2020 &2031

Figure 135: Global Vs. South Africa Growth Comparison

Customize this Report

Explore Intelligence Tailored to Your Business Goals.

Description

Active Pharmaceutical Ingredient Market- Scope of Report

A latest publication by Persistence Market Research on the global active pharmaceutical ingredient market evaluates the opportunities and current market landscape, and provides detailed analysis and updates about corresponding sections affecting the market. The study offers detailed insights on key market dynamics, which include the drivers, restraints, trends, and opportunities in the market. The principal aim of the market study is to present exclusive information about how the market will perform during the forecast period of 2021-2031.

Important indicators for successful growth of the active pharmaceutical ingredient market are presented in this comprehensive report, which include Year-on-Year (Y-o-Y) growth analysis of the market, and compounded annual growth rate (CAGR), which are described in an exhaustive way in Persistence Market Research's study. This research study can support readers to know the demand for active pharmaceutical ingredients and the quantitative development opportunities during the study period.

The research is beneficial for manufacturers of active pharmaceutical ingredients, including investors, manufacturers, service providers, distributors, and suppliers, and can help them in developing suitable business strategies to flourish in the market. Insights and wisdom presented in this Persistence Market Research study can be leveraged by shareholders in the market, industry experts, investors, researchers, and reporters, as well as business enthusiasts.

Market statistics as well as information linked to the macro- as well as micro-economic variables affecting the business scenario in the active pharmaceutical ingredient market are also included in the current study. Depending on potential developments in the market, substantive insights are also encountered in this report. Additionally, by virtue of the data submitted in this report, minor companies and new entrants in the active pharmaceutical ingredient industry can be aided in making suitable company choices to achieve traction in the market.

Key Market Segments

Persistence Market Research’s study on the active pharmaceutical ingredient market offers information divided into three important segments — API, end user, and region. This report offers comprehensive data and information about the important market dynamics and growth parameters associated with these categories.

API
  • Small Molecules
    • Controlled Substances
      • Natural Opioids
      • Semi-synthetic/Synthetic Opioids
    • Non-Controlled Substances
      • NSAIDs
      • Anti-infective
      • Antimicrobial
      • Oral anti-diabetics
      • Anti-hypertensive
      • Others
    • HPAPI
  • Peptides & Oligonucleotides
  • Carbohydrate Drugs
  • Steroidal Drugs
End User
  • Contract Manufacturing Organizations (CMOs)
  • Pharmaceutical Companies
  • Contract Development Manufacturing Organizations (CDMOs)
  • Compounding Pharmacies
Region
  • North America
  • Latin America
  • Europe
  • South Asia
  • East Asia
  • Oceania
  • Middle East & Africa

Key Questions Answered in Report

  • Which regions will continue to remain the most profitable markets for active pharmaceutical ingredients over the coming years?
  • How will changing trends impact the market?
  • How has the COVID-19 crisis impacted market growth?
  • How can market players capture the low-hanging opportunities in developed regions?
  • What are the strategies of stakeholders in the active pharmaceutical ingredient market to shape their position in this landscape?
  • What are the restraining factors that investors need to be aware of and might tackle while investing in the market?
  • What are the developmental trends that will impact the market?
  • How can businesses in the active pharmaceutical ingredient market avail the growth opportunities in developed and emerging sectors?

Research Methodology

In Persistence Market Research’s study, a unique research methodology is utilized to conduct extensive research on the growth of the active pharmaceutical ingredient market, and reach conclusions on the future growth parameters of the market. This research methodology is a combination of primary and secondary research, which helps analysts ensure the accuracy and reliability of the conclusions.

Secondary resources referred to by analysts during the production of the market study include statistics from governmental organizations, trade journals, white papers, and internal and external proprietary databases. Analysts have interviewed senior managers, product portfolio managers, CEOs, VPs, marketing/product managers, and market intelligence managers, who contributed to the development of this report as a primary resource.

Comprehensive information acquired from primary and secondary resources acts as a validation from companies in the market, and makes Persistence Market Research’s projections on the growth prospects of the active pharmaceutical ingredient market more accurate and reliable.

Recommendations

Dearomatic Solvents Market

The global de-aromatic solvents market is estimated to expand at a CAGR of more than 6% over the forecast period of 2021-2031..

Asia Pacific North America Europe Fluorinated Solvents Market

The Asia Pacific Fluorinated Solvents market is expected to register a CAGR of 9.0% over the forecast period (2018–2026)..

Polyester Polyols Market

Polyester Polyols Market was valued at US$ 7,788.7 Mn in 2017 and is projected to rise to a valuation of US$ 11,963.6 Mn by the end of 2025..

Methyl Ethyl Ketone Market

The expected value of the global MEK market is expected to be US$ 800.2 Mn in 2018 and the market is estimated to reach US$ 1,055.6 Mn by the end of forecast period..

Our Clients

Our Clients